Pharma companies should review their commission-based compensation arrangements with independent contractors to address enforcement risk under the Anti-Kickback Statute, in light of recent Department of Justice enforcement.
Ahsin Azim
Advertisement
Associate, Sidley Austin, LLP
Articles by Ahsin Azim
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: Novo Nordisk's Shares Fall After Board Shake-Up
2
Alkermes plc Acquiring Avadel Pharmaceuticals in $2.1 Billion Definitive Agreement
3
Roundup: Pharma Industry Raises Funding Aimed at Advancing the Development and Testing of Rare Disease Treatments
4
Moderna Ceases Development of mRNA-1647 After Failing to Reach Primary Goal in Clinical Trial
5
